Last month, Bausch + Lomb and Nicox S.A. announced that the United States FDA approved the New Drug Application for Vyzulta (latanoprostene bunod ophthalmic solution, 0.024%), the first prostaglandin analog with one of its metabolites being nitric oxide (NO). Vyzulta is indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

According to a company statement, “following topical administration, Vyzulta, a once daily monotherapy with a dual mechanism of action, works by metabolizing into two moieties, latanoprost acid, which primarily works within the uveoscleral pathway to increase aqueous humor outflow, and butanediol mononitrate, which releases nitric oxide to increase outflow through the trabecular meshwork and Schlemm’s canal. The most common ocular adverse events include conjunctival hyperemia, eye irritation, eye pain, and instillation site pain. Increased pigmentation of the iris and periorbital tissue and growth of eyelashes can occur.”

“Vyzulta represents the first FDA-approved therapy developed through our proprietary NO-donating research platform,” said Michele Garufi, chairman and CEO of Nicox, in recent a press release. “We look forward to continuing to leverage our platform in the development of additional innovative ophthalmic compounds.”

For more information, visit www.bausch.com .